A. Mocroft, O. Kirk, and J. Gatell, Chronic renal failure among HIV-1-infected patients, AIDS, vol.21, pp.1119-1146, 2007.

F. A. Dauchy, S. Lawson-ayayi, and R. De-la-faille, Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy, Kidney Int, vol.80, pp.302-311, 2011.

R. Valle and L. Haragsim, Nephrotoxicity as a complication of antiretroviral therapy, Adv Chronic Kidney Dis, vol.13, pp.314-323, 2006.

B. Fernandez-fernandez, A. Montoya-ferrer, and A. B. Sanz, Tenofovir nephrotoxicity: 2011 update, AIDS Res Treat, p.354908, 2011.

P. Flandre, P. Pugliese, and L. Cuzin, Risk factors of chronic kidney disease in HIV-infected patients, Clin J Am Soc Nephrol, vol.6, pp.1700-1707, 2011.

A. Mocroft, O. Kirk, and P. Reiss, Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients, AIDS, vol.24, pp.1667-78, 2010.

R. Scherzer, M. Estrella, and Y. Li, Association of tenofovir exposure with kidney disease risk in HIV infection, AIDS, vol.26, pp.867-75, 2012.

P. Devarajan, Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury, Nephrology (Carlton), vol.15, pp.419-447, 2010.

D. Bolignano, A. Lacquaniti, and G. Coppolino, Neutrophil gelatinaseassociated lipocalin (NGAL) and progression of chronic kidney disease

, Clin J Am Soc Nephrol, vol.4, pp.337-381, 2009.

P. Devarajan, The use of targeted biomarkers for chronic kidney disease, Adv Chronic Kidney Dis, vol.17, pp.469-79, 2010.

L. Landro, J. K. Damas, and T. H. Flo, Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapy, Clin Exp Immunol, vol.152, pp.57-63, 2008.

S. Rodriguez-novoa, P. Labarga, D. 'avolio, and A. , Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations, AIDS, vol.24, pp.1064-1070, 2010.

T. L. Nickolas, C. S. Forster, and M. E. Sise, , vol.82, pp.718-740, 2012.

R. C. Kalayjian, B. Lau, and R. N. Mechekano, Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care, AIDS, vol.26, pp.1907-1922, 2012.

N. Borregaard and J. B. Cowland, Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein, Biometals, vol.19, pp.211-216, 2006.

S. Valle, D. A. Mohan, S. Cheng, and J. T. , Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy, Nephrol Dial Transplant, vol.26, pp.2387-90, 2011.

I. Oboho, A. Abraham, and L. Benning, Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS), NGAL in HIV-infected subjects on tenofovir 2869 JAC Downloaded from, 2012.

K. M. Thrailkill, C. S. Moreau, and G. E. Cockrell, Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus, Endocrine, vol.37, pp.336-379, 2010.

T. A. Rasmussen, D. Jensen, and M. Tolstrup, Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial, PLoS One, vol.7, p.32445, 2012.

L. J. Campbell, T. Dew, and R. Salota, Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients, BMC Nephrol, vol.13, p.85, 2012.

P. Delanaye, E. Rozet, and J. M. Krzesinski, Urinary NGAL measurement: biological variation and ratio to creatinine, Clin Chim Acta, vol.412, p.390, 2011.